Swiss drugmaker Novartis’s (NOVN.VX: Quote, Profile, Research) plan to buy Franco-German rival Aventis (AVEP.PA: Quote, Profile, Research) would entail the creation of two new groups -- one comprised of growth drug areas like oncology and the other for older drugs, which would be spun off, newspaper Le Figaro said on Monday.
